{"entity": "researcher", "timestamp": "2026-08-20T20:48:36.786Z", "family": "Wenthe", "given": "Jessica", "initials": "J", "orcid": "0000-0003-4385-7568", "affiliations": ["Department of Immunology, Genetics and Pathology, Uppsala University, Rudbeck Laboratory C11, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/bc4cbbff70a944af8f477c2a78f79c98.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/bc4cbbff70a944af8f477c2a78f79c98"}}, "publications": [{"entity": "publication", "iuid": "2a39101d25024413973f880034a6b610", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/2a39101d25024413973f880034a6b610.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/2a39101d25024413973f880034a6b610"}}, "title": "A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.", "authors": [{"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Karlsson", "given": "Hannah", "initials": "H"}, {"family": "Gammelg\u00e5rd", "given": "Gustav", "initials": "G"}, {"family": "Wenthe", "given": "Jessica", "initials": "J", "orcid": "0000-0003-4385-7568", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bc4cbbff70a944af8f477c2a78f79c98.json"}}, {"family": "L\u00f6vgren", "given": "Tanja", "initials": "T", "orcid": "0000-0003-2170-0682", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f4a04a7c6e904ff0945c058fcaa3151d.json"}}, {"family": "Amini", "given": "Rose Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278.json"}}, {"family": "Wikstrom", "given": "Kristina I", "initials": "KI"}, {"family": "Essand", "given": "Magnus", "initials": "M"}, {"family": "Savoldo", "given": "Barbara", "initials": "B"}, {"family": "Hallb\u00f6\u00f6k", "given": "Helene", "initials": "H"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Dotti", "given": "Gianpietro", "initials": "G"}, {"family": "Brenner", "given": "Malcolm K", "initials": "MK"}, {"family": "Hagberg", "given": "Hans", "initials": "H"}, {"family": "Loskog", "given": "Angelica", "initials": "A", "orcid": "0000-0001-8583-6138", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/572e5b01b3bd48779252b9020732cb09.json"}}], "type": "clinical trial, phase i", "published": "2018-12-15", "journal": {"title": "Clin. Cancer Res.", "issn": "1557-3265", "volume": "24", "issue": "24", "pages": "6185-6194", "issn-l": "1078-0432"}, "abstract": "The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients with CD19+ B-cell malignancies. Most studies have investigated the second-generation CARs with either CD28 or 4-1BB costimulatory domains in the CAR receptor. Here, we describe the first clinical phase I/IIa trial using third-generation CAR T cells targeting CD19 to evaluate safety and efficacy.\n\nFifteen patients with B-cell lymphoma or leukemia were treated with CAR T cells. The patients with lymphoma received chemotherapy during CAR manufacture and 11 of 15 were given low-dose cyclophosphamide and fludarabine conditioning prior to CAR infusion. Peripheral blood was sampled before and at multiple time points after CAR infusion to evaluate the persistence of CAR T cells and for immune profiling, using quantitative PCR, flow cytometry, and a proteomic array.\n\nTreatment with third-generation CAR T cells was generally safe with 4 patients requiring hospitalization due to adverse reactions. Six of the 15 patients had initial complete responses [4/11 lymphoma and 2/4 acute lymphoblastic leukemia (ALL)], and 3 of the patients with lymphoma were in remission at 3 months. Two patients are still alive. Best predictor of response was a good immune status prior to CAR infusion with high IL12, DC-Lamp, Fas ligand, and TRAIL. Responding patients had low monocytic myeloid-derived suppressor cells (MDSCs; CD14+CD33+HLA-DR-) and low levels of IL6, IL8, NAP3, sPDL1, and sPDL2.\n\nThird-generation CARs may be efficient in patients with advanced B-cell lymphoproliferative malignancy with only modest toxicity. Immune profiling pre- and posttreatment can be used to find response biomarkers.", "doi": "10.1158/1078-0432.CCR-18-0426", "pmid": "30097433", "labels": [], "xrefs": [{"db": "pii", "key": "1078-0432.CCR-18-0426"}, {"db": "EudraCT", "key": "2013-001393-19"}, {"db": "ClinicalTrials.gov", "key": "NCT02132624"}], "notes": [], "created": "2026-08-20T12:12:04.617Z", "modified": "2026-08-20T12:12:04.768Z"}]}